Alamar Biosciences (ALMR) reported a Q1 loss Friday of $1.74 per diluted share, widening from a loss of $0.68 a year earlier.

Revenue for the quarter ended March 31 was $26 million, up from $13.1 million a year earlier.

As of March 31, the company had cash, cash equivalents, and restricted cash of $69.5 million.

Shares of the company were up 2.4% in Friday's premarket activity.